PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...

PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years                  PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to...

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy                Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...